Goldman Sachs analyst Corinne Johnson resumed coverage of ArriVent Biopharma (AVBP) with a Buy rating and $33 price target The firm sees a high probability that the Phase3 FURVENT results demonstrate competitive clinical efficacy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma Announces $75 Million Public Offering
- ArriVent Biopharma 2.5M share Spot Secondary priced at $19.50
- ArriVent Biopharma announces $75M common stock, warrants offering
- ArriVent Biopharma initiated with a Buy at Clear Street
- ArriVent Biopharma price target raised to $44 from $39 at Oppenheimer